Jake Shortt
Overview
Explore the profile of Jake Shortt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
1551
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tedjaseputra A, Tey A, Nalpantidis A, Grigoriadis G, Fleming S, Vilcassim S, et al.
Intern Med J
. 2025 Mar;
PMID: 40052282
Background: After pharmaceutical benefits scheme approval of midostaurin for fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus...
2.
Goodall E, Tedjaseputra A, Hui C, Walker P, Shortt J
Pathology
. 2024 Dec;
57(3):375-377.
PMID: 39706757
No abstract available.
3.
Shembrey C, Yang R, Casan J, Hu W, Chen H, Singh G, et al.
Sci Adv
. 2024 Dec;
10(51):eadl0731.
PMID: 39693429
Single-nucleotide variants (SNVs) are extremely prevalent in human cancers, although most of these remain clinically unactionable. The programmable RNA nuclease CRISPR-Cas13 has been deployed to specifically target oncogenic RNAs. However,...
4.
Ngo T, Goh A, Dorwal P, Leong E, Shortt J, Fedele P, et al.
Pathology
. 2024 Dec;
57(3):340-347.
PMID: 39672769
Haematological malignancies are being increasingly defined by gene rearrangements, which have traditionally been detected by karyotype, fluorescent in situ hybridisation (FISH) or reverse-transcriptase polymerase chain reaction (RT-PCR). However, these traditional...
5.
Kim W, Shortt J, Zinzani P, Mikhailova N, Radeski D, Ribrag V, et al.
Clin Cancer Res
. 2024 Nov;
31(1):65-73.
PMID: 39531538
Purpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate...
6.
Tatarczuch M, Lewis K, Gunjur A, Shaw B, Poon L, Paul E, et al.
EJHaem
. 2024 Aug;
5(4):709-720.
PMID: 39157596
Background: Despite recent advances, optimal therapeutic approaches applicable to subpopulations with primary central nervous system (CNS) lymphoma outside of clinical trials remain to be determined. Methods: We performed a retrospective...
7.
Toohey T, Shortt J, John N, Al-Qureshi S, Wickremasinghe S
Am J Ophthalmol Case Rep
. 2024 Aug;
36:102095.
PMID: 39114297
Purpose: To determine the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in the setting of optic disc edema secondary to hematologic malignancies. Observations: The report features two patients (one...
8.
Yeung D, Shanmuganathan N, Reynolds J, Branford S, Walia M, Yong A, et al.
Blood
. 2024 Aug;
144(19):1993-2001.
PMID: 39102630
Asciminib is a myristoyl site BCR::ABL1 inhibitor approved for patients with chronic-phase chronic myeloid leukemia (CP-CML) failing ≥2 prior lines of therapy. The Australasian Leukaemia and Lymphoma Group conducted the...
9.
Della Porta M, Garcia-Manero G, Santini V, Zeidan A, Komrokji R, Shortt J, et al.
Lancet Haematol
. 2024 Jul;
11(9):e646-e658.
PMID: 39038479
Background: The preplanned interim analysis of the COMMANDS trial showed greater efficacy of luspatercept than epoetin alfa for treating anaemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk myelodysplastic syndromes....
10.
Costacurta M, Sandow J, Maher B, Susanto O, Vervoort S, Devlin J, et al.
FEBS J
. 2024 Jul;
291(22):4892-4912.
PMID: 38975872
Immunomodulatory imide drugs (IMiDs) are central components of therapy for multiple myeloma (MM). IMiDs bind cereblon (CRBN), an adaptor for the CUL4-DDB1-RBX1 E3 ligase to change its substrate specificity and...